| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0037 | AF116616 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0055 | AK094838 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0092 | ASLNC00339 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0227 | BANCR | osteosarcoma | real-time PCR | osteosarcoma cell lines and clinical specimens | down-regulated | N/A | BANCR expression was significantly associated with large tumor size; MG-63 cell proliferation | 27051014 | |
| EL0227 | BANCR | osteosarcoma | RT-PCR, Western blotting and CCK-8 assay | MG-63 cells | up-regulated | expression | After the construct pcDNA3.1-BANCR (BRAF-regulated lncRNA 1) was transfected into MG-63 cells, RT-PCR, Western blotting and CCK-8 assay showed that BANCR was positively correlated with baicalein. | 25893737 | |
| EL0228 | BC002350 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0233 | BC091525 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0240 | BE503655 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | osteosarcoma | qPCR, knockdown etc. | cell lines (Saos-2) | up-regulated | expression | qRT-PCR showed that ANRIL is highly expressed in these cancer cells compared to normal fibroblasts. Depletion of ANRIL increased p15 expression, with no impact on p16 or ARF (alternative reading frame) expression, and caused cell-cycle arrest at the G2/M phase, leading to inhibition of proliferation of H1299 and HeLa cells. | 26408699 | Lnc2Cancer |
| EL0329 | DANCR | osteosarcoma | Lentivirus-mediated (shRNA) to silence osteosarcoma cell lines U2OS and Saos-2 | osteosarcoma cell lines U2OS and Saos-2 | up-regulated | N/A | knockdown of ANCR significantly inhibited the proliferation of U2OS and Saos cells and colony formation of U2OS cells | 26986815 | |
| EL0371 | ENO1 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0499 | FGFR3-AS1 | osteosarcoma | real-time quantitative PCR | osteosarcoma | up-regulated | N/A | FGFR3-AS1 inhibits xenograft tumor growth of osteosarcoma cells | 27022737 | |
| EL0502 | FKBP10 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0508 | FOXC2-AS1 | osteosarcoma | microarray, qPCR, Western blot, knockdown etc. | cell lines (MG63, SaoS2, U-2OS) | up-regulated | interaction | lncRNA ODRUL was higher in different doxorubicin-resistant OS cell lines and lower in different doxorubicin-sensitive OS cell lines. Moreover, we showed that lncRNA ODRUL was increased in specimens of OS patients with a poor chemoresponse and lung metastasis. We further demonstrated that lncRNA ODRUL inhibition could inhibit OS cell proliferation, migration, and partly reversed doxorubicin resistance in vitro. In addition, we found that the expression of classical drug resistance-related ATP-binding cassette, subfamily B, member 1 (ABCB1) gene was decreased after the lncRNA ODRUL knockdown. Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells. | 26408180 | Lnc2Cancer |
| EL0508 | FOXC2-AS1 | osteosarcoma | microarray, qRT-PCR | three sets of doxorubicin-resistant MG63/DXR and their paired parental MG63 cells (fold-change >2.0, P<0.05 and FDR <0.05). | up-regulated | expression | The patients of lower expression of it may survive longer than those of higher expression, which suggest that it may serve as a biomarker to predict the chemoresponse and prognosis of steosarcoma patients. | 26463625 | |
| EL0570 | HIF1A-AS2 | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | up-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL0571 | HIF2PUT | osteosarcoma | qPCR, knockdown etc. | osteosarcoma tissue, cell lines (SAOS2, MG63, U2OS) | differential expression | expression | HIF2PUT expression levels were positively correlated with HIF-2a in osteosarcoma tissues. Overexpression of HIF2PUT markedly inhibited cell proliferation and migration, decreased the percentage of CD133 expressing cells, and impaired the osteosarcoma stem sphere-forming ability of the MG63 cells. Furthermore, altering the expression of HIF2PUT resulted in a concomitant change to HIF-2a mRNA expression. | 25434862 | Lnc2Cancer |
| EL0582 | HOTTIP | osteosarcoma | qPCR, knockdown etc | osteosarcomas tissues and matched adjacent non-tumor tissues, cell lines(MG-63, HOS) | up-regulated | expression | We found that HOTTIP expression was up-regulated in OS tissues, and correlated with advanced clinical stage and distant metastasis. OS patients with high HOTTIP expression level had poorer overall survival than those with low HOTTIP expression. Multivariable Cox proportional hazards regression analysis suggested that increased HOTTIP expression was an independent prognostic factor of overall survival in OS patients. Moreover, the results of in vitro assays showed that the suppression of HOTTIP in OS cells significantly reduced cell proliferation, migration and invasion ability | 26617868 | Lnc2Cancer |
| EL0600 | HULC | osteosarcoma | qPCR etc. | osteosarcoma tissue, cell lines(MG-63, U2OS, SAOS-2 etc.) | up-regulated | expression | In the present study, we demonstrated that HULC was significantly up-regulated in osteosarcoma tissues and cell lines compared with normal controls, and over-expression of HULC was correlated with clinical stage and distant metastasis. Moreover, higher HULC expression was associated with shorter overall survival of osteosarcoma patients.e, decreased expression of HULC markedly suppressed osteosarcoma cell proliferation, migration, and invasion. | 26045809 | Lnc2Cancer |
| EL0670 | LINC00901 | osteosarcoma | microarray, qPCR, FISH etc. | osteosarcoma tissue, cell lines (U2OS, SAOS-2, HOS etc.) | down-regulated | mutation | These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. | 20048075 | LncRNADisease Lnc2Cancer |
| EL0682 | LINC01024 | osteosarcoma | qPCR, Western blot, knockdown etc. | cell lines (U2OS, SAOS-2) | up-regulated | expression | We employed qPCR to analyze MA-linc1 levels in four cell lines: U2OS and H1299 cells, as well as the human embryonic lung fibroblasts, WI38, and another human osteosarcoma cell line, SAOS-2, each expressing the conditionally active E2F1. This analysis demonstrated that activation of the ectopic E2F1 resulted in a significant increase in MA-linc1 RNA levels in all four cell lines. | 26337085 | Lnc2Cancer |
| EL0853 | MALAT1 | osteosarcoma | N/A | N/A | N/A | expression | Osteosarcoma patients' survival is significantly associated with MALAT-1 expression levels. | 20951849 | LncRNADisease |
| EL0853 | MALAT1 | osteosarcoma | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
| EL0853 | MALAT1 | osteosarcoma | qPCR etc. | osteosarcoma tissue | up-regulated | N/A | The expression of MALAT-1, IMPDH2, FTL and RHOA significantly correlated with response to chemotherapy. Expression of all four genes was increased in the poor responder group that are valuable markers for the prediction of osteosarcoma therapy outcome. Especially IMPDH2 and FTL are promising candidates for the stratification of osteosarcoma patients into low- and high-risk groups. Owing to their involvement in drug action these genes may further be potential targets for the modulation of drug sensitivity. | 17660802 | Lnc2Cancer |
| EL0853 | MALAT1 | osteosarcoma | qPCR, knockdown etc. | osteosarcoma tissue, cell lines (MG63, Saos-2, hFOB1.19, MNNG/HOS) | up-regulated | expression | We observed that MALAT1 expression was up-regulated in human osteosarcoma cell lines and tissues. In vitro knockdown of MALAT1 by siRNA significantly inhibited cell proliferation and migration, and induced cell cycle arrest and apoptosis in osteosarcoma cells. In addition, MALAT1 knockdown markedly suppressed the formation of tubular network structures and caused breakage of stress fibers in osteosarcoma cell lines U2OS and MNNG/HOS. | 26575981 | Lnc2Cancer |
| EL0853 | MALAT1 | osteosarcoma | qPCR, Western blot, knockdown etc. | osteosarcoma tissue, cell lines (SAOS2, MG63, U2OS) | up-regulated | expression | In our research, the MALAT1 messenger RNA (mRNA) was highly expressed in human osteosarcoma tissues, and its expression level was closely correlated with pulmonary metastasis. Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed its metastasis in vitro and vivo. MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway. | 25431257 | Lnc2Cancer |
| EL0861 | MEG3 | osteosarcoma | quantitative real-time PCR (qRT-PCR) | osteosarcoma tissues | down-regulated | expression | The expression of lncRNA MEG3 was associated with clinical stage and istant metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low lncRNA MEG3 expression had a shorter overall survival (log-rank test, P<0.05). Furthermore, multivariate analysis revealed that decreased expression of lncRNA MEG3, advanced clinical stage and distant metastasis were all independent predictors to overall survival of osteosarcoma patients. Downregulation of lncRNA MEG3 was associated with poor overall survival of osteosarcoma. LncRNA MEG3 could be a useful biomarker for progression and prognosis of osteosarcoma. | 26823857 | |
| EL0954 | MYHAS | osteosarcoma | microarray, qPCR etc. | primary osteosarcoma tissue | down-regulated | N/A | The results demonstrated that ASLNC21868, ASLNC22124, ASLNC23844, ASLNC24587, BE503655 and BC050642 were over-regulated and that ASLNC00339, ASLNC11435, ASLNC13387 and ASLNC18814 were under-regulated in the osteosarcoma samples compared with normal samples. The qPCR results and microarray data are consistent. | 23466354 | Lnc2Cancer |
| EL1223 | SNHG12 | osteosarcoma | western blot, quantitative real-time polymerase chain reaction, RNA interference, cell migration assays, flow cytometry | primary osteosarcoma (n = 20) and adjacent normal tissues (n = 20), the osteosarcoma cell lines, SAOS-2, MG-63, U-2 OS, and the human osteoblast cell line hFOB (OB3) | up-regulated | interaction | Upregulation of AMOT mRNA was associated with upregulation of SNHG12. Knockdown of SNHG12 reduced the expression of angiomotin in osteosarcoma cells and suppressed cell proliferation and migration but did not affect cell apoptosis. The lncRNA SNHG12 promotes cell proliferation and migration by upregulating AMOT gene expression in osteosarcoma cells in vivo and in vitro. | 26486328 | |
| EL1399 | TUG1 | osteosarcoma | qPCR etc. | osteosarcoma tissue, cell lines (U2OS etc.) | up-regulated | N/A | We found significantly higher TUG1 and n377360 expression levels in osteosarcoma tissues compared with matched non-tumorous tissues. Suppression of TUG1 and n377360 expression by siRNA significantly impaired the cell proliferation potential of osteosarcoma cells. Furthermore, inhibition of TUG1 expression significantly promoted osteosarcoma cell apoptosis. The overexpression of TUG1 and n377360 in osteosarcoma specimens and the functional role of TUG1 and n377360 regarding cell proliferation and apoptosis in an osteosarcoma cell line provided evidence that the use of TUG1 or n377360 may be a viable but an as yet unexplored therapeutic strategy in tumors that over express these factors. | 23725133 | Lnc2Cancer |
| EL1402 | TUSC7 | osteosarcoma | Cell counting kit 8 (CCK-8) assay, western blot | osteosarcoma tissues | down-regulated | interaction | Cell counting kit 8 (CCK-8) assay revealed that after silence of TUSC7, cell proliferation ability increased and the colony formation ability also increased. After silence of TUSC7, the proapoptotic Bcl2 expression was downregulated. Compared with negative control group, silence of TUSC7 significantly promoted tumor growth in vivo. Thus, we demonstrated that TUSC7 could be a potential tumor suppressor in osteosarcoma. | 26781978 | |
| EL1402 | TUSC7 | osteosarcoma | deletion analysis, reciprocal repression, quantitative PCR arrays and in situ hybridization of tissue microarrays | N/A | down-regulated | N/A | a tumor suppressor unit in osteosarcoma and to suppress tumor cell growth. ,loc285194 is a p53 transcription target; ectopic expression of loc285194 inhibits tumor cell growth both in vitro and in vivo..loc285194 is a p53-regulated tumor suppressor, which acts in part through repression of miR-211. | 23558749 | |
| EL1402 | TUSC7 | osteosarcoma | microarray, qPCR, FISH etc. | osteosarcoma tissue, cell lines (U2OS, SAOS-2, HOS etc.) | down-regulated | mutation | These CNAs (copy number alterations) in osteosarcoma often involve the noncoding RNAs LOC285194 and BC040587. | 20048075 | LncRNADisease Lnc2Cancer |